IGC Pharma, Inc. (NASDAQ:IGC) | WebDisclosure

Basculer en Français

9805	Companies
196647	Keywords
127661	Articles
104550	Press releases

Home
Companies
IGC Pharma, Inc.

PRESS RELEASE

published on 11/14/2024 at 14:30, 1 year 2 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 1 year 2 months ago

IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids

Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
BRIEF

published on 11/06/2024 at 14:35, 1 year 2 months ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
PRESS RELEASE

published on 11/06/2024 at 14:30, 1 year 2 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 1 year 3 months ago

IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest

IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
BRIEF

published on 10/17/2024 at 14:35, 1 year 3 months ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 year 3 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRIEF

published on 10/03/2024 at 15:05, 1 year 4 months ago

IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge
BRIEF

published on 10/03/2024 at 15:05, 1 year 4 months ago

IGC Pharma remporte deux prix lors du concours AI PREPARE Challenge du NIH

Technologie De L'IA Innovation Dans Le Domaine De La Santé IGC Pharma Prédiction De La Maladie D'Alzheimer Défi Du NIH
PRESS RELEASE

published on 10/03/2024 at 15:00, 1 year 4 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC Pharma, Inc. wins 2 awards in the PREPARE Challenge for Alzheimer's research with its MHAS entry. Recognition highlights leadership in AI for disease prediction

Artificial Intelligence Healthcare Innovation Alzheimer's Research IGC Pharma PREPARE Challenge

Accesswire

Published on 02/05/2026 at 01:35, 4 hours 27 minutes ago

Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 6 hours 2 minutes ago

Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 7 hours 37 minutes ago

55 North Mining Announces Flow-Through Financing
Published on 02/04/2026 at 18:00, 12 hours 2 minutes ago

Lithium South AGSM Update
Published on 02/04/2026 at 16:15, 13 hours 47 minutes ago

Trans Canada Gold Enters into an Option Agreement with Bear Mountain Gold Mines to Acquire a 60% Interest in the Harrison Lake District Scale Gold Property, with $10.0 Million Dollars in Prior Exploration Expenditures

View all ACCESSWIRE

EQS Group

Published on 02/04/2026 at 20:54, 9 hours 8 minutes ago

Elmos Semiconductor SE is planning to distribute 36 million Euro to shareholders for the fiscal year 2025
Published on 02/04/2026 at 20:36, 9 hours 26 minutes ago

EQS-Adhoc: Elmos Semiconductor SE approves share buyback program via the stock exchange of 10 million Euro and dividend proposal of 1.50 Euro per share for fiscal year 2025
Published on 02/04/2026 at 20:00, 10 hours 1 minute ago

Belgium's Ingmar De Vos elected to Executive Board of International Olympic Committee
Published on 02/04/2026 at 18:55, 11 hours 7 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/04/2026 at 18:40, 11 hours 21 minutes ago

Robin Zeng: Unlocking the Sustainable Energy Era with Zero-Carbon Technology

Les Echos

Published on 02/04/2026 at 18:04, 11 hours 58 minutes ago

Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 11 hours 58 minutes ago

Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 12 hours 17 minutes ago

Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 12 hours 17 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 02/04/2026 at 17:45, 12 hours 17 minutes ago

Janvier 2026

View all LES ECHOS COMFI WIRE